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Purpose: Recent experimental studies have established the feasibility of therapeutic 
angiogenesis; in all cases, this has been achieved with local administration of angiogenic 
growth factors. This study was designed to investigate the hypothesis that systemic 
administration of an angiogenic growth factor specifically mitogenic for endothelial 
cells-vascular endothelial growth factor (VEGF)-could augment collateral vessel 
development in a rabbit ischemic hindlimb model. 
Methods: Ten days after the ligation of the external lilac artery and excision of the common 
and superficial femoral arteries in one limb of New Zealand white rabbits, heparin 
(800 IU, n = 13), VEGF (1 mg, n = 3; 5 mg, n = 5), heparin (800 IU) + VEGF (1 mg, 
n = 5; 5 rag, n = 7), or saline solution (n = 8) was injected as a single bolus in a marginal 
ear vein. Collateral vessel formation and limb perfusion were assessed 10 and 30 days after 
treatment. 
Results: Animals in both VEGF-treated groups had a significantly higher (p < 0.01) 
increase in calf blood pressure ratio at day 10 (control, 0.44 _+ 0.02; heparin, 0.47 -+ 0.02; 
VEGF, 0.60 +- 0.01; heparin + VEGF, 0.61 + 0.02) and day 30 (control, 0.49 + 0.05; 
heparin, 0.48 + 0.02; VEGF, 0.70 --- 0.03; heparin + VEGF, 0.73 --. 0.03). Both 
VEGF-treated groups had a significantly higher (p < 0.05) angiographic score at day 30 
(control, 0.28 --. 0.01; heparin, 0.28 -- 0.01; VEGF, 0.37 -+ 0.01; heparin + VEGF, 
0.38 +- 0.02). Maximum flow reserve at day 30 in the ischemic limb was higher (p < 0.05) 
in VEGF-treated rabbits (control, 1.87 +- 0.07; heparin, 1.92 -+ 0.08; VEGF, 
2.42 + 0.16; heparin + VEGF, 2.33 -+ 0.12). Capillary densitywas higher ~ < 0.01) in 
the ischemic muscles of VEGF-treated rabbits (control, 156---10/mm2; heparin, 
178 -+ 8/mm2; VEGF, 230 -+ 10/mm2; heparin + VEGF, 233 -+ 8/mm2). 
Conclusions: This series of in vivo experiments demonstrates that intravenous adminis- 
tration of VEGF, with or without heparin, results in both anatomic and physiologic 
evidence of enhanced collateral vessel formation in the rabbit ischemic hindlimb. 
Single-bolus ystemic administration of VEGF may be a feasible therapeutic strategy in 
patients with lower-extremity ischemia. (J VASC SURG 1995;21:314-25.) 
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A considerable proportion of patients with severe 
lower extremity vascular insufficiency have disease so 
extensive that direct revascularization techniques 
cannot be undertaken successfully. In such patients, 
therapeutic strategies designed to augment native 
collateral vessel blood flow represent a novel means of
achieving distal limb perfusion. Recent studies have 
established the feasibility of use of recombinant 
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angiogenic growth factors to expedite collateral 
artery development in animal models of hindlimb 
ischemia. Endothelial ceil growth factor, 1 basic fibro- 
blast growth factor, 2and vascular endothelial growth 
factor (VEGF), 3 administered by repeated intramus- 
cular injections ~'2 or as an intraarterial bolus, 3 have all 
been shown to enhance angiogenesis in the rabbit 
ischemic hindlimb model. Although these results 
may be of major importance for patients with limb 
ischemia, the need for multiple injections or an 
invasive procedure to deliver the angiogenic growth 
factor may limit use of this promising approach. In 
addition, although a local therapy would be well 
suited for patients with severe and localized isease, 
it may have some disadvantages in those with diffuse 
disease because many therapeutic interventions 
would be needed. We thus decided to investigate he 
angiogenic effects of a systemic administration of 
vascular endothelial growth factor, a heparin- 
binding, endothelial cell-specific mitogen, 4 in a rabbit 
model of hindlimb ischemia. Because a protective 
and potentiating effect of heparin on VEGF binding 
has been demonstrated in vitro, s we analyzed the 
effects of a single intravenous bolus dose of VEGF 
alone and of VEGF combined with heparin. 
METHODS 
Animal model. The physiologic response to 
systemic administration f VEGF was investigated in 
a rabbit ischemic hindlimb model described previ- 
ously. 6 All protocols were approved by the St. 
Elizabeth's Medical Center Institutional Animal Care 
and Use Committee. Forty-one male New Zealand 
white rabbits (3.5 to 4 kg) (Pine Acre Rabbitry, 
Norton, Mass.) were anesthetized with a mixture of 
ketamine (50 mg/kg) and acepromazine (0.8 mg/kg) 
after premedication with xylazine (2 mg/kg). A 
longitudinal incision was performed, extending infe- 
riorly from the inguinal ligament o a point just 
proximal to the patella. The limb in which the 
incision was made (right versus left) was determined 
randomly at the time of surgery. Through this 
incision, the femoral artery was dissected free along 
its entire length with use of surgical loops; all 
branches of the femoral artery, including the inferior 
epigastric vessels, deep femoral, lateral circumflex, 
and superficial epigastric, were also dissected free. 
After dissection of the popliteal and saphenous 
arteries distally, the external iliac artery and all of the 
arteries listed above were ligated with 4-0 silk 
(Ethicon, Somerville, N.J.). Finally, the femoral 
artery was completely excised from its proximal 
origin as a branch of the external lilac artery to the 
Fig. 1. Rabbit model of hindlimb ischemia. Aortic an- 
giogram obtained 20 days after ligation of right external 
iliac (EIA) and excision fright common and superficial 
femoral arteries. Blood flow to ischemic limb depends on 
collateral vessels (arrow) issuing from internal itiac arte U 
07A). 
point distally where it bifurcates to form the saphe- 
nous and popliteal arteries. The excision of the 
femoral artery esults in retrograde propagation of 
thrombus and occlusion of the external i iac artery. 
Consequently, blood flow to the ischemic limb 
depends on collateral vessels issuing from the internal 
iliac artery (Fig. 1). 
Recombinant human VEGF16 s. The 165- 
amino acid homodimeric species of recombinant 
human VEGF was purified from transfected Chinese 
hamster ovary ceils as previously described. 7 The 
purity of the material was assessed by a silver-stained 
SDS/PAGE gel and the presence of a single NH 2- 
te rmina l  amino acid sequence. 
Intravenous administration fVEGF. A period 
of 10 days was allowed to elapse before initiation of 
treatment to allow stabilization and recovery from 
the surgical procedure. On the tenth postoper- 
ative day (day 0), the animals were randomly assigned 
to four groups. After a baseline angiogram was 
recorded (see below), a catheter (25-gauge × a/4- 
inch Butterfly; Abbott, Chicago, Ill.) was inserted 
into a marginal ear vein. Eight rabbits received a
single intravenous bolus dose of VEGF (1 mg, 
n = 3; 5 mg, n = 5) in 3 ml saline solution 
containing 0.1% albumin (Sigma Chemical Co., St. 
Louis, MoO; 13 rabbits received only heparin in a 
single bolus dose (800 IU); 12 rabbits were given a 
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Fig. 2. Effect of systemic administration of VEGF on 
revascularization in ischemic limb model: calf blood 
pressure ratio measured at days 0, 10 and 30. Asterisks 
representp < 0.01 vs control and heparin groups. 
single intravenous bolus dose of VEGF (1 mg, 
n = 5; 5 mg, n = 7) 5 minutes after intravenous 
administration of heparin (800 IU). Eight rabbits 
received only intravenous vehicle (3 ml saline solu- 
tion containing 0.1% albumin) and were used as a 
control group. 
Lower-limb calf blood pressure ratio. Calf 
blood pressure was measured in both hindlimbs on 
day 0 (before treatment), day 10, and day 30. On 
each occasion, the hindlimbs were shaved and 
cleaned, the pulse of the posterior final artery was 
identified with a Doppler probe, and the systolic 
blood pressure in each limb was measured by use of 
standard techniques. The calf blood pressure ratio 
was defined for each rabbit as the ratio of systolic 
pressure of the ischemic limb to the systolic pressure 
of the normal imb. 
Angiography. Diagnostic angiography was per- 
formed on day 0 (before treatment), day 10, and day 
30. A 3F infusion catheter (Tracker-18; Target 
Therapeutics, San Jose, Calif.) was introduced into 
the right common carotid artery through a small 
cutdown, and advanced to the lower abdominal aorta 
with a 0.014-inch guide wire (Hi-Torque Floppy II; 
Advanced Cardiovascular Systems, Temecuia, Calif.) 
under fluoroscopic guidance. The tip of the catheter 
was advanced to the entrance of the internal iliac 
artery of the ischemic limb. After intraarterial injec- 
tion of 0.25 mg of nitroglycerin (Solopak Labora- 
tories, Franklin Park, Ill.), 5 ml of contrast media 
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Fig. 3. Angiographic score at days 0, 10, and 30.Asterisks 
representp < 0.05 vs control and heparin groups. 
(Isovue-370; Squibb Diagnostics, New Brunswick, 
N.J.) was injected with an automated angiographic 
injector (Medrad, Pittsburgh, Pa.) at a rate of 
i ml/sec. Serial images of the ischemic hindlimb were 
then recorded on 105 mm spot film at a rate of 
1 film/see for 10 seconds. 
The analysis of collateral development was per- 
formed on the 4-second angiograms. A composite of 
5 mm 2 grids was placed over the medial thigh area. 
The total number of grid intersections in the medial 
thigh area, as well as the total number of intersections 
crossed by a contrast-opacified artery, were counted 
by a single observer blinded to the treatment 
regimen. An angiographic score was calculated for 
each film as the ratio of grid intersections crossed by 
opacified arteries divided by the total number of grid 
intersections in the medial thigh. 
Assessment of blood flow parameters. Blood 
flow was assessed on day 30 in the ischemic limb and 
in the normal imb with use of a Doppler guide wire. 8 
The tip of the 3F infusion catheter was positioned 
2 cm above the iliac bifurcation. After intraarterial 
injection of nitroglycerin (0.25 mg), 5 ml of contrast 
media was injected at a rate of 1 ml/sec. Serial images 
of the aortoiliac bifurcation were then recorded on 
105 mm spot film at a rate of 1 film/see for 5 sec. 
The 0.018-inch Doppler guide wire (Cardiomet- 
rics, Inc., Mountain View, Calif.) used in these 
experiments has been described previously. 8-11 
Briefly, a 12 MHz piezoelectric transducer is 
mounted at the tip of the distal floppy shapeable 
segment of the wire. The Doppler wire records a 
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Fig. 4. Assessment ofblood flow in internal i iac artery of 
ischemic limb at day 30. There were no changes inrest flow 
in four groups. In contrast, maximum flow after injection 
of papaverine 2 mg was significantly higher in VEGF- 
treated groups. Asterisks representsp < 0.05 vs control and 
heparin groups. 
real-time, spectral analysis of the Doppler signal, 
from which the average peak velocity (APV) (the 
temporal average of the instantaneous peak velocity 
waveform) is calculated and displayed on line. In this 
study, the wire was advanced through the 3F infusion 
catheter (positioned at the origin of the common lilac 
artery) to the proximal segment of the internal iliac 
artery supplying the ischemic limb. Measurements 
were performed at rest and after bolus injection of 
papaverine (Sigma Chemical Co.), 2 mg (shown in 
preliminary dose-response experiments to induce 
maximal increase in velocity in this model), in 0.4 ml 
of saline solution through the infusion catheter. Flow 
reserve was calculated as the ratio of APV after 
papaverine injection divided by APV at baseline. 
The Doppler wire was then pulled back from the 
internal ilac artery and readvanced to the proximal 
segment of the external lilac artery of the normal 
limb. The distal tip of the 3F infusion catheter was 
positioned at the origin of the common iliac artery,. 
Blood flow velocity was again recorded from the 
Doppler wire at rest and after papaverine injection. 
The angiographic luminal diameters of the inter- 
nal iliac artery in the ischemic limb and the external 
lilac artery in the normal imb were determined with 
an automated edge-detection system that has previ- 
ously been validated. 12 The film selected for analysis 
was scanned with a high-resolution video camera; the 
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Fig. 5. Effect of systemic administration of VEGF on 
capillary density in medial thigh muscles of ischemic limbs 
at day 30. Asterisks represents p < 0.01 vs control and 
heparin groups. 
signal produced by the video camera was digitized 
and displayed on a video monitor. Centerlines were 
traced manually for a 10 mm segment beginning 
immediately distally to the tip of the Doppler wire. 
The contours were subsequently detected automati- 
caUy on the basis of the weighted sum of first and 
second derivative functions applied to the digitized 
brightness information. The vascular diameter was 
then measured at the site of the Doppler sample 
volume (5 mm distal to the wire tipS). Cross-sectional 
area was calculated assuming a circular lumen. 
Doppler scanning-derived flow was calculated as 
QD = ('rrd2/4)( 0"5 x APV), where QD = Doppler 
scanning-derived time average flow, d = vessel di- 
ameter, and APV = time average of the spectral peak 
velocity, s The mean velocity was estimated as 
0.5 x APV by assuming a time-averaged parabolic 
velocity profile across the vessel. The Doppler- 
scanning-derived flow calculated in this fashion has 
been shown to correlate with flow measurements 
determined by electromagnetic flow meters both in 
vitro and in vivo. 8 
Capillary density and capillary/musde fiber 
ratio. The anatomic effects of intravenous VEGF 
were further examined by measuring the number of" 
capillaries in light microscopical sections taken from 
the ischemic hindlimbs and comparing the findings 
with similar measurements in the normal hindlimb 
controls. Tissue specimens were obtained as trans- 
verse sections from the adductor muscle and the 
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Fig. 6. Alkaline phosphatase taining of ischemic hindlimb muscle of rabbits in control (A), 
heparin (B), VEGF (C), and heparin + VEGF (D) groups. Dark staining indicates capillaries 
(counterstained with eosin). 
semimembranous muscle of both limbs of each 
animal at the time of sacrifice (day 30). These two 
muscles were chosen for light microscopical analysis 
because they are the two principal muscles of the 
medial thigh, and each was originally perfused by the 
deep femoral artery, which was ligated when the 
common/superficial femoral artery was excised. 
Muscle samples were embedded in O.C.T. com- 
pound (Miles, Inc., Elkhart, Ind.) and snap-frozen in 
liquid nitrogen. Multiple frozen sections (5 txm in 
thickness) were then cut from each specimen on a 
cryostat (Miles, Inc.) so that the muscle fibers were 
oriented in a transverse fashion, and then two 
sections were placed on glass slides. The tissue 
sections were stained for alkaline phosphatase with an 
indoxyl-tetrazolium ethod to detect capillary endo- 
thelial cells as previously described 2,13,14 and coun- 
terstained with eosin. Capillaries were counted under 
a x 20 objective to determine the capillary density 
(mean number of capillaries/mm2). Twenty different 
fields from the two muscles were randomly selected 
for the capillary counts. To ensure that analysis of 
capillary density was not overestimated asa result of 
muscle atrophy or underestimated because of inter- 
stitial edema, the capillary/muscle fiber ratio was 
determined in each histologic section. The counting 
scheme used to compute the capillary/muscle fiber 
ratio was otherwise identical to that used to compute 
capillary density. 
Statistical analysis. All results are xpressed as 
mean --- standard error. Statistical comparisons were 
performed with an analysis of variance. When a 
significant difference was detected, multiple- 
comparison analysis was performed with the 
Student-Newman-Keuls test. A p value < 0.05 was 
considered statistically significant. 
RESULTS 
Effects of  intravenous VEGF in the ischemic 
limb. Calf blood pressure ratio was similar in all 
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Fig. 7. Selective internal iliac angiogram and Dopplerflow measurements in control animal 
(A-E) and in VEGF-treated animal (F-J). Angiography was performed on days 0 (A, F), l0 
(B, G), and 30 (C, H). There is marked increase in progression of angiographically visible 
collateral vessels in VEGF-treated animal (F-H) as compared with nontreated, ischemic control 
(A-C). Doppler flow measurements were performed at day 30 in internal iliac artery ofischemic 
limb. Flow reserve (FR) was substantially higher in VEGF-treated rabbit (J) than in control (E). 
groups at day 0 (control, 0.26 _+ 0.04; heparin, 
0.30 + 0.02; VEGF, 0.33 + 0.02; heparin + 
VEGF, 0.31 _+ 0.02;p = NS). Byday 10, the blood 
pressure ratio had improved in all groups; in the 
VEGF-treated groups, however, the blood pressure 
ratio was uperior (p < 0.01) to that in the control 
and heparin-trea~ed groups (control, 0.44 _+ 0.02; 
heparin, 0.47 + 0.02; VEGF, 0.60 _+ 0.01; hep- 
arin + VEGF, 0.61 + 0.02) (Fig. 2). By day 30, the 
blood pressure ratio in the two VEGF-treated groups 
had increased further and was again significantly 
higher (p < 0.01) than that in the control and 
heparin groups (control, 0.49 _+ 0.05; heparin, 
0.48 + 0.02; VEGF, 0.70 _+ 0.03; heparin + 
VEGF, 0.73 ___ 0.03). As shown in Fig. 2, calf blood 
pressure ratio in the heparin-alone group was similar 
at all three time points studied to that in the control 
group. The increased blood pressure ratio observed 
in the rabbits treated with VEGF alone was not sig- 
nificantly different from that in the rabbits treated 
with heparin + VEGF. 
The quantitative analysis of collateral vessel devel- 
opment in the medial thigh is summarized in Fig. 3. 
Before treatment (day 0), there were no signifi- 
cant differences in angiographic scores in the four 
groups (control, 0.20 _+ 0.01; heparin, 0.22 _+ 
0.01; VEGF, 0.21 _+ 0.02; heparin + VEGF, 
0.24 _ 0.02; p = NS). Afterward, a progressive in- 
crease in angiographic score was observed. By day 30 
the angiographic s ore in both VEGF-treated groups 
exceeded (p < 0.05) that in the control and hep- 
arin-alone groups (control, 0.28 __+ 0.01; heparin, 
0.28 -+ 0.01; VEGF, 0.37 + 0.01; heparin + 
VEGF, 0.38 _+ 0.02). 
Blood flow parameters were assessed in the inter- 
nal lilac artery of the ischemic limb at day 30. Flow at 
rest was similar in all groups (control, 19.2 __+ 1.2 
ml/min; heparin, 19.5 + 0.9 ml/min; VEGF, 
20.2 _+ 1.4 ml/min; heparin + VEGF, 20.2 _+ 0.9 
ml/min; p = NS). Maximum flow after administra- 
tion of 2 mg papaverine was significantly higher 
(p < 0.05) in both VEGF-treated groups, as com- 
pared with the maximum flow in the control and 
heparin groups (control, 36.2 -+-+-- 3.4 ml/min; hepa- 
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Fig. 8. Representative internal iliac angiograms recorded at day 30 in rabbits in control (A), 
heparin (B), VEGF (C), and heparin + VEGF (D) groups. Development of collateral 
circulation ismarkedly amplified in both VEGF-treated groups as compared with control (A) 
and heparin-alone (B) groups. 
rin, 37.3 + 2.3 ml/min; VEGF, 48.5 +_ 2.7ml/min; 
heparin + VEGF, 46.3 + 1.8 ml/min) (Fig. 4). The 
significant increase in maximum flow in the VEGF- 
treated animals resulted in a significantly higher 
(2 < 0.05) flow reserve (ratio of maximum flow after 
papavarine to ftow at rest) than in the control and 
heparin groups (control, 1.87 m 0.07; heparin, 
1.92 +_ 0.08; VEGF, 2.42 _+ 0.16; heparin + 
VEGF, 2.33 +_ 0.12). 
The histologic evaluations of the medial thigh 
muscles in the ischemic limbs on day 30 revealed that 
the capillary density was significantly higher (p < 
0.01) in the VEGF-treated groups than in the control 
and heparin groups (control, 156 - 10/ram2; hepa- 
tin, 178 + 8/mm2; VEGF, 230 - 10/ram2; hepa- 
tin + VEGF, 233 -+ 8/mm 2) (Figs. 5 and 6). The 
analysis of capillary/muscle fiber ratio produced 
similar results (control, 0.39 + 0.04; heparin, 
0.48 _+ 0.02; VEGF, 0.67 -+ 0.04; heparin + 
VEGF, 0.66 + 0.04). 
Fig. 7 consists of" representative internal iliac 
angiograms recorded from a control and a VEGF- 
treated animal. In the control animal, collateral rtery 
development in the medial thigh progressed only 
slightly in serial angiograms recorded at days 0, 10, 
and 30 (Fig. 7, A to C). In contrast, in the animal 
from the VEGF-treated group, improvement of 
collateral artery development was typically observed 
at days 10 and 30, as compared with the baseline (day 
0) angiogram (Fig. 6, F-H). The physiologic equiva- 
lent of the anatomic improvement in the VEGF- 
treated animals is represented by an increase in flow 
reserve (Fig. 7,J). 
Representative examples of internal iliac anglo- 
grams at day 30 from each of the four experimental 
groups are compared in Fig. 8 to demonstrate the 
greater proliferation of collateral vessels in the 
VEGF-treated groups (Fig. 8, C and D) compared 
with the control and heparin-only groups (Fig. 8, A 
and C, respectively). Fig. 8, D also illustrates more 
rapid reconstitution f the distal popllteal and tibial 
arteries typically seen in VEGF-treated limbs. 
The impact of the dose of VEGF on the 
angiogenic response is shown in Table I. The blood 
pressure ratio, angiographic s ore, flow parameters, 
and capillary density were similar in the animals 
treated with 1 mg and 5 mg of VEGF. 
Effects of VEGF in the normal limb. Blood 
flow parameters were also assessed in the external li ac 
artery of the normal, nonischemic limbs on day 30. 
As shown in Table II, there were no differences 
between resting flow, maximum flow, or flow reserve 
in the VEGF-treated, heparin-treated, and control 
animals. 
The capillary density in the medial thigh muscle 
of the nonischemic limb was similar in all four 
groups (control, 186 -+ 7; heparin, 196 m 14; 
VEGF, 203 -+ 9; heparin + VEGF, 205 _+ 6; 
p = NS). The capillary/muscle fiber ratio was also 
similar (control, 0.57 _+ 0.03; heparin, 0.56 m 0.02; 
VEGF, 0.58 -+ 0.03; heparin + VEGF, 0.58 -+ 
0.01;p = NS). 
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Table I. Assessment of angiogenesis in the ischemic limb 30 days after the intravenous 
administration f 1 or 5 mg of VEGF * 
VEGF 1 mg (n = 8) VEGF 5 mg (n = 12) 
Blood pressure ratio 0.68 +- 0.02 0.75 ± 0.03 NS 
Aslgiographic score 0.35 -+ 0.03 0.39 + 0.02 NS 
Resting flow (ml/min) 18.7 _+ 1.3 21.3 _+ 0.8 NS 
Maximum flow (ml/min) 46.0 -+ 2.3 48.0 ± 1.9 NS 
Flow reserve 2.48 _+ 0.15 2.27 + 0.1I NS 
Capillary density. (mm 2) 239 _+ i{ 1 227 _+ 7 NS 
Capillary/muscle fiber ratio 0.67 +- 0.04 0.66 ± 0.04 NS 
~Because VEGF alone and heparin + VEGF had similar angiogenic effects, the data from both groups were pooled for this comparison. 
Values are mean _+ SE. 
Table II. Flow parameters measured in the external i iac artery of the normal nonischemic limb 
30 days after treatment 
Control Heparin VEG_F Heparin + VEGF 
(n = g) (n = 13) (n = 8) (n = 12) 
Resting flow (ml/min) 18.3 -+ 1.2 20.7 _+ 1.9 19.2 + 0.5 22.3 ± 1.3 NS 
Maximum flow (ml/min) 42.1 ± 2.7 42.8 _+ 2.8 42.6 _+ 1.7 47.0 + 2.1 NS 
Flow reserve 2.34 + 0.16 2.11 _+ 0.09 2.26 _+ 0.17 2.13 ± 0.10 NS 
Values are mean _+- SE. 
DISCUSSION 
Our results demonstrate hat systemic adminis- 
tration of VEGF, achieved in this study by adminis- 
tering a single intravenous bolus of 1 or 5 mg, is 
sufficient o enhance revascularization in a rabbit 
model of lower extremity ischemia. Other studies 
have recently established the feasibility of use of 
recombinant angiogenic growth factors to expedite 
collateral artery development in animal models of 
hindlimb ischemia. >a Baffour et al.2 demonstrated 
that basic fibroblast growth factor (bFGF) increased 
the growth of collateral vessels in a rabbit model of 
acute lower limb ischemia. In that study, the animals 
were treated aily for 2 weeks with intramuscular 
injection of bFGF directly into the ischemic limb. Pu 
et al., 1 using the same model of rabbit hindlimb 
ischemia, found that endothelial cell growth factor, 
administered into the ischemic muscles daily for i0 
days, promoted revascularization. We 3 have recently 
achieved similar results with a single intraarterial 
injection of VEGF given directly into the internal 
iliac artery of the ischemic limb. To our knowledge, 
this study is the first demonstration that systemic 
administration f an endothelial cell-specific growth 
factor in one bolus dose may result in site-specific 
therapeutic angiogenesis. 
VEGF-induced angiogenesis. Several methods 
were used to document angiogenesis in this study. 
Anatomic evidence of angiogenesis in response to 
VEGF administration was observed at two levels. 
Necropsy examination documented an increase in 
vascularity at the capillary level, consistent with the 
classic definition of angiogenesis formulated by 
Klagsbrun and Folkman. 1~ In addition, systematic 
quantification fangiographic recordings established 
that development of angiographically visible collat- 
eral arteries in file VEGF-treated animals exceeded 
that in the controls. 
The physiologic equivalent of these anatomic 
findings, and thus the extent o which angiogenesis 
was therapeutic, was assessed by serial measurements 
of the lower limb blood pressure ratio and evaluation 
of flow parameters in the ischemic limb. At both day 
10 and day 30, the calf blood pressure ratio in the 
VEGF-treated groups significantly exceeded that in 
the control groups; this increase was likely to have 
been a consequence of better arterial reconstiturion in 
the limb with a higher pressure. Flow parameters 
were assessed in the internal iliac artery of tile 
ischemic limb on day 30 with a Doppler wire and 
quantitative angiography. Previous studies have es- 
tablished that the APV recorded with this method 
correlates closely with flow determined by electro- 
magnetic flowmeters for lumen diameters varying 
between 0.79 and 4.76 mm in straight vascular 
segments. 8 The size and straight orientation of the 
internal lilac artery from which the Doppler sample 
volume was recorded are thus appropriate for the 
Doppler wire and indicate that velocity and flow were 
estimated with reasonable accuracy. Blood flow at 
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rest was similar in the VEGF-treated and control 
animals; in contrast, maximum flow provoked by 
intraarterial injection of papaverine, a direct smooth- 
muscle dilator, was significantly higher in the VEGF- 
treated groups. These results agree with those of 
previous studies that show that most models of 
chronic ischemia re characterized bya small deficit in 
resting flow, 16,x7 a factor that complicates demon- 
stration of a favorable response to angiogenic therapy 
at rest. In contrast, maximum flow reserve, typically 
more severely and consistently impaired in these 
models, is more useful for investigating the physi- 
ologic impact of therapeutic angiogenesis. Thus in 
this study the significantly increased flow seen in the 
VEGF groups after papaverine-induced vasodilation 
is a measure of the enhanced capacity of the treated 
limb to increase flow in response to increased demand 
presumably asa result of the enlarged capacity of the 
collateral bed to deliver blood downstream. 
Effects of heparin. Our results uggest that the 
systemic administration of a single bolus dose of 
VEGF is as effective as a combination of heparin and 
VEGF. Coadministration f heparin and VEGF was 
inspired by the findings of two previous in vitro 
studies. Soker et al.s observed that circulating %- 
macroglobulin covalently binds to VEGF; once 
complexed, VEGF is no longer free to bind its 
receptors on vascular endothelium and is thereby 
inactivated. The binding and consequent inactivation 
of VEGF by ec2-macroglobulin was completely in- 
hibited by 20 ~g/ml of heparin. Moreover, Gitay- 
Goren et al}8 demonstrated that addition of exog- 
enous heparin could restore binding of iodine 
125-labeled VEGF to endothelial cells in which such 
binding had been completely inhibited by digestion 
with heparinase. The present similarity between 
blood pressure ratio, angiographic score, capillary 
density, and blood flow in the groups in which VEGF 
was given with and without heparin suggests that 
such an effect is unlikely to be of major clinical 
importance. 
A single systemic bolus dose of heparin alone has 
had no effect on collateral formation in our rabbit 
model of hindlimb ischemia. Heparin alone has been 
inferred to be angiogenic n some studies in human 
beings ~9'2° and has been reported to be angiogenic n
vivo in different models of collateral vessel forma- 
tion. 17m Several mechanisms have been suggested to
explain this effect. In addition to its interactions with 
VEGF, heparin protects acidic and basic fibroblast 
growth factors from inactivation, 22 releases basic 
fibroblast growth factor from the extracellular ma- 
trix, 2a and stimulates the secretion and activation of 
plasminogen act ivator .  24'2s In the pig model of 
coronary collateral formation, continuous treatment 
with heparin is angiogenic, 17but administration of
heparin twice daily in bolus injections i  not. 26 These 
results, taken together with those of this study, 
underscore certain differences between heparin- and 
VEGF-induced angiogenesis: continuous, prolonged 
treatment appears to be required with heparin, 
whereas a single bolus dose of VEGF elicits a 
substantive r sponse. 
Systemic administration. Although we believe 
that this study represents he first demonstration f 
collateral vessel formation after systemic administra- 
tion of an angiogenic growth factor, Beck et al.27 
recently demonstrated that systemic administration 
of transforming growth factor-[31 accelerates wound 
healing. Specifically, a single intravenous bolus of 
100 to 500 lag/kg of transforming growth factor-[31 
increased wound-breaking strength in rats with 
glucocorticoid-impaired h aling to the normal levels 
in controls. These results how that systemic growth 
factor administration may, for selected purposes, 
be sufficiently effective to constitute site-specific 
therapy. At first glance this profound response to a 
single bolus administration f VEGF seems contra- 
dictory in view of its relatively short biologic half-life 
(less than 6 minutes, Ferrara et al, unpublished data, 
1993). Such a protracted response maybe feasible, 
however, if proteoglycan constituents of the extra- 
cellular matrix bind VEGF for some undetermined 
period of time. It should be noted in this regard that, 
although VEGF~6 s is soluble and therefore luted 
from the cell surface more readily than the less soluble 
isoforms VEGF189 or VEGF206, it still demonstrates 
substantial ffinity for heparin. Previously published 
data by Houck et al.,28 in fact, indicate that up to 50% 
of VEGF16 s is retained extracellularly by heparin- 
binding proteoglycans. 
With respect o blood pressure ratio, angio- 
graphic score, and capillary density, the amount of 
angiogenesis we observed here after injection of 1 or 
5 mg of VEGF was similar to that seen in the same 
model after intraarterial dministration of 0.5 or 1 
mg ofVEGF, a The increase in maximum blood flow 
was also similar to that observed after intraarterial 
administration of 0.5 mg of VEGF. 29 These data 
suggest that the systemic administration f VEGF is 
an intriguing alternative to intraarterial injection. 
The precise mechanisms responsible for initiation 
of angiogenesis remain enigmatic. In this study, flow 
parameters and capillary density in the nonischemic 
control imb were unaffected by VEGF treatment, 
suggesting that ischemia may be a prerequisite for 
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VEGF-induced angiogenesis. Whereas VEGF re- 
ceptors are known to be constitutively exprcssed 
on endothelial cells, ischemia or hypoxia, previously 
shown to upregulate transcription of endogenous 
VEGF mP, NA, a°,31 may also produce further up- 
regulation of endothelial cell receptors for VEGF. 
Whatever the reason for the apparent specificity 
of VEGF for ischemic areas, the finding is impor- 
tant because it suggests that the possible side ef- 
fects of a systemic administration would be mini- 
mized. 
Recent studies have found that administration of 
recombinant angiogenic growth factors enhances 
collateral formation in several animal models.~a In all 
these experiments, however, the growth factor (en- 
dothelial cell growth factor, ~ basic fibroblast growth 
factor, 2 or VEGF 3) was administered locally into the 
ischemic limb, in one or multiple doses, by the 
intramuscular or intraarterial route. Demonstration 
that a single systemic administration of VEGF is 
effective has important clinical implications. An 
intravenous bolus injection is clearly easier to admin- 
ister than multiple injections into ischemic muscles or 
selective catheterization of the target artery. In 
addition, systemic administration may be more 
appropriate than local administration for patients in 
whom vascular occlusive disease involving several 
sites in the lower limb circulation (e.g., the iliac, 
femoral, and infrapopliteal arteries) has resulted in 
multiple levels of limb ischemia (e.g., thigh, calf, 
foot). 
In conclusion, this study demonstrates that a 
systemically administered angiogenic mitogen can 
produce clinically significant improvement in perfu- 
sion of an ischemic limb. In so doing, it further 
enhances the potential of this unique therapeutic 
approach to the treatment of peripheral arterial 
occlusive disease. 
We are grateful to Ms. Marianne Kearney for assistance 
with histologic studies and to Mrs. Mickey Neely and 
Ren& Robillard for assistance in the preparation of this 
manuscript. 
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DISCUSSION 
Dr. Allen D. Callow (St. Louis, Mo.). I have some 
difficulty with the assumptions in behalf of and the 
conclusions offered with this model. 
First, what truly new information does this use of 
VEGF provide as compared with the same use ofbFGF and 
platelet-derived growth factor? 
Second, the results are not surprising, in view of the fact 
that you published the same in the Journal of Clinical 
Investigation earlier this year. 3 The only change is that in this 
report you used an intravenous as opposed to an intraar- 
terial route. 
But more importantly, what is the mechanism by which 
VEGF, a mitogen specific for endothelial cells that has no 
demonstrated proliferative ffect on smooth muscle cells, 
appears in these experiments o have an effect, not only on 
smooth muscle cells but also on extracellular matrix 
synthesis and accumulation? New blood vessels cannot be 
built on endothelial cells alone. By contrast, bFGF and 
platelet-derived growth factor are mitogeus for both 
endothelial cells and smooth muscle cells. 
You claim that VEGF is site specific, at least in this 
model. Fm not so sure. Is it not conceivable that VEGF 
simply causes random endothelial cell proliferation and that 
collateral vessels will develop naturally in the control, but 
a bit faster in the treated animals? 
Another very serious problem: With a biologic half-life 
of only a few minutes in vivo, what is the mechanism for 
this effect nearly a month after administration of a single 
bolus and 10 days after the ischemic episode? 
Figs. 2 and 3, blood pressure ratio and angiographic 
score, respectively, show a gradual approach in the control 
animal of both these parameters to those in the treated 
animal with time. This suggests that in this model with 
normal, undiseased vessels, collateral flow may increase 
over time and ultimately equal that in the treated limb. Why 
were observations stopped at 30 days when the curve of 
collateralization was still going up in the control animal? 
Finally, what is the clinical potential of this study? 
Frankly I don't know. I do know that in the human limb, 
with ischemia the result of severe atherosclerosis, collateral 
development may already have reached its maximum, and 
very little can be done to improve it. 
Dr. James F. Symes. I agree that we do not know or 
completely understand the mechanism by which VEGF 
brought about the changes that we saw in this study. We 
have also worked to some extent with other growth factors 
such as bFGF, and endothelial cell growth factor, which is 
an acidic FGF, and w%know that similar results can be 
obtained with both of those growth factors. The fact that 
VEGF is endothelial cell specific and is secreted makes it 
somewhat different from the fibroblast growth factors, and 
it was for that reason we thought it might be more 
powerful in terms of initiating angiogenesis in this 
particular setting. Because of some in vitro evidence that 
vascular endothelial growth factor and basic FGF can be 
synergistic, we have used such a combination. This is a 
descriptive study. We believe the evidence from the study 
is impressive, but we clearly do not know exactly by what 
mechanisms the effect of VEGF comes about. It's been 
recently pointed out, for example, that VEGF can produce 
vasodilation by stimulating nitric oxide release, so that 
there may be a component of this present as well. 
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With regard to the use of intravenous versus intraar- 
terial administration, the reason we tried this particular 
series of experiments was to prove that intravenous 
administration wouldn't work. Genentech, the major 
suppliers of this growth factor, wanted to see if it could be 
used intravenously, and we therefore carried out this study. 
We had the bias that it would not be as effective and were 
somewhat surprised by the results that we obtained. 
With regard to the issue of site specificity, we have 
begun some studies using 12SI-labeled VEGF, administered 
systemically and locally, and have some preliminary results, 
that do suggest hat, in fact, with 12~I labeling, we can 
demonstrate increased concentration of VEGF in the 
ischemic limb compared with the nonischemic limb. 
Dr. Michael T. Watldns (Boston, Mass.). Did you use 
a carrier for the VEGF? Most growth factors are sensitive 
to circulating serine proteases and must be protected from 
degradation by use of carrier proteins. If you did use a 
carrier, was this protein also administered to the control 
animals? This is an important point because a foreign 
protein by itself can mediate an inflammatory eaction. The 
study of angiogenesis is often complicated by experimental 
conditions, which inadvertently favor inflammation. Are 
you certain that you have not generated an inflammatory 
response in your experimental animals with a foreign 
protein and avoided a similar response by use of protein- 
free solutions for your controls? 
Dr. Symes. The only carrier used in this study was 
0.1% rabbit albumin. No other vehicle was used to 
administer the VEGF. We recognize the concern with 
regard to this issue of inflammation, and it brings us back 
to one of Dr. Callow's questions with regard to the control 
animals. We have done numerous preliminary studies with 
this model, which show that the changes in blood pressure 
ratio are stable from 30 days to beyond 3 months and do 
not progressively increase, as he intimated. 
